1. Home
  2. GRI vs HTCR Comparison

GRI vs HTCR Comparison

Compare GRI & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.18

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$2.68

Market Cap

3.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
HTCR
Founded
2018
2009
Country
United States
Japan
Employees
N/A
44
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.4M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
GRI
HTCR
Price
$2.18
$2.68
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$160.00
N/A
AVG Volume (30 Days)
34.1K
55.9K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
87.84%
EPS Growth
N/A
414.29
EPS
N/A
0.22
Revenue
N/A
$30,407,229.00
Revenue This Year
N/A
$123.26
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$12.23
Revenue Growth
N/A
39.19
52 Week Low
$0.18
$0.15
52 Week High
$6.70
$3.97

Technical Indicators

Market Signals
Indicator
GRI
HTCR
Relative Strength Index (RSI) 44.50 48.19
Support Level $2.12 $0.29
Resistance Level $2.23 $3.85
Average True Range (ATR) 0.12 0.32
MACD -0.01 -0.15
Stochastic Oscillator 51.16 10.00

Price Performance

Historical Comparison
GRI
HTCR

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

Share on Social Networks: